OCGN — Ocugen, Inc.
9 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about OCGN (2026-11-05)
- Ocugen anticipates top-line data for its OCU400 Phase III trial in Q1 2027, aiming for three BLAs by 2028.
- The company reported Q3 2026 earnings, highlighting $84.6M in cash and investments with a runway extending into 2028.
- A vote on authorizing 250 million additional shares is scheduled for December 22, pending the settlement of $130M notes.
| Bluesky | 3 | community |
| GDELT | 3 | news |
| RSS Bundle | 2 | news |
| SEC EDGAR 8-K | 1 | filings |